Lorena Fariñas-Madrid

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Stéphanie Lheureux, Ana Oaknin, Swati Garg et al. · Clinical Cancer Research · 2020 · 126 citations · Full text

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Nicoletta Colombo, Elena Biagioli, Kenichi Harano et al. · The Lancet Oncology · 2024 · 89 citations

Gynecological Surgery, Medicine, Metronomic Therapy +6

A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)

Juan Francisco Grau-Béjar, Lorena Fariñas-Madrid, Ana Oaknin · International Journal of Gynecological Cancer · 2019 · 78 citations

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Ignace Vergote, José Alejandro Pérez Fidalgo, Erika Hamilton et al. · Journal of Clinical Oncology · 2023 · 65 citations · Full text